A phase 2b study of efficacy and safety of Radspherin® in patients with colorectal carcinoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2023 New trial record
27 Oct 2023 According to an Oncoinvent media release, company announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study for Radspherin in patients with peritoneal carcinomatosis from colorectal cancer following the promising indications of safety and efficacy from the RAD-18-002 Phase 1/2a clinical trial.
27 Oct 2023 According to an Oncoinvent media release, company plans to start the trial in Q2 of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com